PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72285-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)72285-9/fulltext
Title :
PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72285-9&doi=10.1016/S1098-3015(11)72285-9
First page :
A328
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
444